From CNBC: 2025-04-01 08:38:00

Eli Lilly is suing compounding pharmacies Strive and Empower for allegedly producing altered versions of its weight-loss and diabetes drugs, Zepbound and Mounjaro, after the FDA banned such practices. The companies are accused of marketing their products as personalized, potentially luring customers away from Lilly’s FDA-approved treatments.

Despite FDA restrictions, some compounding pharmacies are still producing tirzepatide, the active ingredient in Lilly’s drugs, with slight modifications to circumvent the ban. Strive and Empower supply tirzepatide to telehealth sites, potentially impacting the market for Lilly’s products. The lawsuits will test Lilly’s legal standing against compounding pharmacies post-FDA ban.

This legal battle could set a precedent for other pharmaceutical companies like Novo Nordisk, whose drugs may face similar challenges post-FDA restrictions. The outcome of the lawsuits against Strive and Empower may shape future regulations and enforcement in the pharmaceutical industry.



Read more at CNBC: Eli Lilly sues Strive and Empower over compounded tirzepatide